Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


The Original Article was published on 12 April 2006

The article ‘Can super-antibody drugs be tamed?’ (Nature 440, 855–856; 2006) contained two errors. Steve Anderton researches autoimmune disease, not the use of antibodies to overcome cancer. And he did not state that the CD25 receptor may be a safer target for antibody therapies than CD28; instead, he suggested that CD25 may be of some use as a marker for regulatory T cells, and that other costimulatory molecules, such as CD154, may represent safer targets for immunomodulatory antibodies. Nature apologizes for any confusion.

Additional information

The online version of the original article can be found at 10.1038/440855a

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Corrections. Nature 441, 141 (2006).

Download citation

  • Published:

  • Issue Date:

  • DOI:


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing